Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
E: info@sartorius.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,673.90 | 173.70 | -2.21% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 20,354.44 | 2,495.37 | -10.92% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 33,141.70 | 638.88 | -1.89% |
| NZX 50 Index | 11,912.68 | 312.60 | -2.56% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,476.70 | 191.10 | -2.49% |
| SSE Composite Index | 3,114.20 | 17.62 | 0.57% |